Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22256433 | 0.92 | HDAC7 (0.57) | HDAC7CYP46A1SLC6A3SLC6A4GABRA1 | |
| SCHEMBL22256431 | 0.92 | HDAC7 (0.57) | HDAC7CYP46A1SLC6A3SLC6A4GABRA1 | |
| SCHEMBL8180022 | 0.90 | CYP46A1 (0.58) | HDAC7CYP46A1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1775361 | 0.87 | CYP46A1 (0.72) | HDAC7CYP46A1SLC6A3SLC6A4GABRA1 | |
| SCHEMBL13817373 | 0.86 | CYP46A1 (0.56) | HDAC7CYP46A1SLC6A3SLC6A4HTT | |
| SCHEMBL2390009 | 0.85 | HDAC7 (0.60) | HDAC7CYP46A1PTGDR2MAPTMEN1 | |
| SCHEMBL28056479 | 0.85 | HDAC7 (0.60) | HDAC7CYP46A1SLC6A3PTGDR2MAPT | |
| SCHEMBL26572779 | 0.84 | S1PR4 (0.49) | HDAC7CYP46A1SLC6A3SLC6A4GABRG2 | |
| SCHEMBL22256466 | 0.84 | HDAC7 (0.49) | HDAC7CYP46A1SLC6A3SLC6A4GABRA1 | |
| SCHEMBL12121707 | 0.84 | GABRA1 (0.62) | CYP46A1SLC6A3SLC6A4GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637433-B2 | Histone deacetylase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2026-05-26 | — | — | US | disclosed |
| US-20240109847-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-04-04 | — | — | US | disclosed |
| EP-4267539-A1 | HISTONE DEACETYLASE INHIBITORS | The University of Queensland (AU) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| EP-0873123-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| EP-0873123-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | HDAC7 1393/4885CYP46A1 487/4885SLC6A3 2958/4885 |
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | HDAC7 3525/4885CYP46A1 138/4885SLC6A3 4263/4885 |
| US-12637433-B2 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC3 | HDAC7 8/4885CYP46A1 3969/4885SLC6A3 4199/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | HDAC7 545/4885CYP46A1 158/4885SLC6A3 2092/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | HDAC7 545/4885CYP46A1 158/4885SLC6A3 2092/4885 |
| US-20240109847-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC11 | HDAC7 7/4885CYP46A1 1404/4885SLC6A3 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.